Neuroprotection and prevention of oxaliplatin-induced neuropathy with Huangqi Guizhi Wuwu Decoction: a 12-center randomized, double-blind trial with mechanistic validation.
PhytomedicineJul 1, 2026 (epub)
Xiaohe Sun, Yan Fang, Xueying Yang et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter, randomized, double-blind trial evaluated the efficacy of Huangqi Guizhi Wuwu Decoction (HQGZWWD) in preventing oxaliplatin-induced peripheral neuropathy (OIPN) in 360 adults with colorectal cancer undergoing XELOX chemotherapy. The study found that grade ≥2 chronic OIPN occurred in 21.3% of the HQGZWWD group compared to 38.6% in the placebo group (OR, 0.43; P<0.001).
Key findings
- Grade ≥2 chronic OIPN occurred in 21.3% of the HQGZWWD group vs 38.6% in the placebo group (OR, 0.43; P<0.001).
- Adverse events were comparable between HQGZWWD and placebo groups (OR, 1.27; P=0.524).
- HQGZWWD significantly attenuated chemotherapy-induced elevations of pro-inflammatory cytokines and oxidative stress markers.
Why it matters
Oxaliplatin-induced peripheral neuropathy is a common and debilitating side effect of chemotherapy. Effective preventive strategies like HQGZWWD could improve patient quality of life and treatment adherence.